The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pieris Pharmaceuticals; Principa Biopharma; Rexahn Pharmaceuticals; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
 
Sam Chang
Consulting or Advisory Role - Altor BioScience; Bristol-Myers Squibb; ferring; Janssen Oncology; Merck; Pfizer; Photocure; Urogen pharma
Research Funding - NantCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Maxwell Meng
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Gilead Sciences; Roche
Consulting or Advisory Role - Auris
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Badrinath R. Konety
Research Funding - Bristol-Myers Squibb; Merck; Photocure
 
Gary D. Steinberg
Stock and Other Ownership Interests - UroGen pharma
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; CG Oncology; Ferring; Janssen; Merck; Pfizer; Photocure; Seagen
 
Juergen Gschwend
No Relationships to Disclose
 
Hiroyuki Nishiyama
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Chugai Pharma (Inst); MSD (Inst); Takeda (Inst)
Research Funding - Astellas Pharma; Ono Pharmaceutical
 
Joan Palou
No Relationships to Disclose
 
John A Taylor
Honoraria - ASCO; Bristol-Myers Squibb; Photocure
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Ferring
Patents, Royalties, Other Intellectual Property - PCT/US11/21721. Use of Isoxazoline compounds and compositions in bladder cancer. Inventors: Taylor JA and Sielecki TM
Other Relationship - Photocure
 
Alexandre Lambert
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Li Zhu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Toshiki Maeda
Employment - Bristol-Myers Squibb
 
Bradley Raybold
Employment - Bristol-Myers Squibb
 
Bruce S. Fischer
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Chandrika Jeyamohan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dimitrios Zardavas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Fred Witjes
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Nucleix; Roche; Sanofi/Aventis; Tocagen